Skip to main content
. 2023 Feb 24;6:218. doi: 10.1038/s42003-023-04576-w

Fig. 6. BX795 mediated TBK1 inhibition restores energy homeostasis and provides neuroprotection in glaucomatous hRGCs.

Fig. 6

a Measurements of cell area normalized OCR from the ATP rate assay of hRGCs treated with DMSO or 1 μg/ml BX795 for 24 h. b Calculated total-, mito-, and glyco- ATP production rates from the ATP rate assay. n = 3–5. c, d Measurements of cell area normalized c OCR and d PER from the glycolytic rate assay. e Calculated mitoOCR/glycoPER from the glycolytic rate assay. n = 3–4. f, g Measurements of cell area normalized OCR from the Mito Stress Test of f H7-hRGCWT and g H7-hRGCE50K, and h spare respiratory capacity after 24 h treatment with 1 μg/ml BX795. n = 6. i–l Caspase-3/7 activity was measured using ApoToxGlo-Triplex assay kit in hRGCs after 16 h pretreatment with BX795 and then 24 h or 48 h treatment with DMSO, 1 μg/ml BX, 10 μM CCCP, or BX795 and CCCP treatments. Treatment conditions were normalized to the DMSO control for respective hRGC type. ٭p-value < 0.05, ٭٭p-value < 0.01, ٭٭٭p-value < 0.001. Unpaired student’s t-test between independent datasets. Error bars are SEM.